drugset / Trial / NCT06187285

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

NCT06187285

RandomizedParallel-groupOpen-labelTreatment

Summary

Clinical guidelines from professional organizations have recommended the use of multidose insulin regimens as the preferred therapy for glycaemic control in patients admitted to hospital in a non-intensive-careunit setting. The use of a basal-bolus regimen with a once daily basal insulin and rapid-acting insulin analogs before meals has been shown to improve glycaemic control and to reduce the rate of hospital complications in general medical and surgical patients with type 2 diabetes.The basal-bolus regimen however is labour intensive, requiring several insulin injections, and is associated with a high risk of hypoglycaemia. Hypoglycaemia has been reported in 12% to 32% of patients in general medicine and surgery with type 2 diabetes treated with basal-bolus insulin regimens.Because of these limitations, alternative treatment regimens are needed that could improve glycaemic control and clinical outcomes, while facilitating care and minimising the risk of hypoglycaemia in patients with diabetes.

Timeline

Start
2024-01-01
Primary completion
2025-05-01
Completion
2025-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg
Comparator Sitagliptin Small molecule 100 mg